A5015273283- Multiple Myeloma Research and Treatments
- Prostate Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Health Systems, Economic Evaluations, Quality of Life
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Cancer survivorship and care
- Reproductive Health and Technologies
- Reproductive Biology and Fertility
- Colorectal Cancer Screening and Detection
- Prostate Cancer Treatment and Research
- Family Support in Illness
- Global Public Health Policies and Epidemiology
- Glutathione Transferases and Polymorphisms
- Urinary Tract Infections Management
- Clinical practice guidelines implementation
- Neonatal Respiratory Health Research
- Protein Degradation and Inhibitors
- Pelvic floor disorders treatments
- Infant Development and Preterm Care
- Cancer Risks and Factors
- Histone Deacetylase Inhibitors Research
- Patient-Provider Communication in Healthcare
- Urinary Bladder and Prostate Research
- Neonatal and fetal brain pathology
University of Leeds
2018-2024
University of Warwick
2021
St James's University Hospital
2016-2020
Addenbrooke's Hospital
2009
Abstract Objective Clinical options for managing nonmetastatic prostate cancer (PCa) vary. Each option has side effects associated with it, leading to difficulty in decision‐making. This study aimed assess the relationship between patient involvement treatment decision‐making and subsequent decision regret (DR), quantify impact of health‐related quality life (HRQL) outcomes on DR. Methods Men living United Kingdom, 18 42 months after diagnosis PCa, were identified from registration data sent...
Background Prostate cancer and its treatment may impact physically, psychologically socially; affecting the health-related quality of life men their partners/spouses. The Life After Cancer Diagnosis (LAPCD) study is a UK-wide patient-reported outcomes which will generate information to improve health well-being with prostate cancer. Methods analysis Postal surveys be sent survivors (18–42 months postdiagnosis) in all 4 UK countries (n=∼70 000). Eligible identified and/or verified through...
To provide data on the prevalence of urinary, bowel and sexual dysfunction in Northern Ireland (NI), to act as a baseline for studies prostate cancer outcomes aid service provision within general population.A cross-sectional postal survey 10 000 men aged ≥40 years NI was conducted age-matched distribution living with cancer. The EuroQoL five Dimensions Levels (EQ-5D-5L) 26-item Expanded Prostate Cancer Composite (EPIC-26) instruments were used enable comparisons outcome studies. Whilst...
More men are living following a prostate cancer (PCa) diagnosis. They may need support to maximize the quality of their survival. Physical and psychological impacts PCa widely documented. Less is known about social impacts. We aimed identify key factors associated with distress PCa. The Life After Prostate Cancer Diagnosis study UK national cross-sectional survey 18–42 months post diagnosis Men (n = 58 930) were invited participate by diagnosing centre including 82% English NHS Trusts 111)...
Prostate cancer incidence, treatment, and survival rates vary throughout the UK, but little is known about regional differences in quality of survival.To investigate variations patient-reported outcomes between UK countries English Cancer Alliances.A cross-sectional postal survey prostate survivors diagnosed 18-42mo previously.Urinary, bowel, sexual problems vitality were patient reported using Expanded Index Composite (EPIC-26) questionnaire. General health was also self-assessed. Regional...
<h3>Background</h3> Treatment for cancer can leave 1 in 3 young people sub-fertile. With survival rates around 85%, evidence to support treatment and management of subfertility is an urgent research priority. Those most at risk sub-fertility may be offered ovarian or testicular tissue storage before gonadotoxic treatment. To date, over 1600 children the UK have stored tissue, but fertility restoration not guaranteed: Worldwide, 200 live births been reported using with no from use tissue....
40 Background: Prostate cancer (PCa) outcome studies are frequently restricted to specific disease stage or treatments. Interpretation may be through lack of population control data & selection bias. We report a whole evaluation health-related quality life (HRQL) following diagnosis PCa compared general (GenPop) cohort. Methods: Cross-sectional postal survey all men diagnosed with in the UK 18-42 months earlier. Measures generic HRQL (EQ-5D) and outcomes (EPIC-26 interventions for...